Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors during the central nervous procedure, conolidine modulates alternate molecular targets. A Science Advances study observed that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://davidp245wis9.targetblogs.com/profile